Cyclophosphamide (Cytoxan): A review on relevant pharmacology and clinical uses

Journal of the American Academy of Dermatology

Volumn 11, Issue 6, 1984, Pages 1115-1126

  Ahmed, A Razzaque ^a   Hombal, Shiril M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ACETYLCYSTEINE; AZATHIOPRINE; CARCINOGEN; CYCLOPHOSPHAMIDE; DRUG ANALOG; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; PHYTOHEMAGGLUTININ; PREDNISONE;

ADVERSE DRUG REACTION; ALLERGIC VASCULITIS; ALOPECIA; AUTOIMMUNE DISEASE; BLADDER; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CARCINOGENESIS; CHEMICAL CARCINOGENESIS; DRUG MECHANISM; ENDOCRINE SYSTEM; GONAD; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTOXICATION; LESION; PERIPHERAL VASCULAR SYSTEM; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW; SKIN TOXICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY; TOXICITY; WEGENER GRANULOMATOSIS;

EID: 0021744448     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(84)80193-0     Document Type: Review

References (150)

1. Oxazaphosphorines
2. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide
3. Alkylating properties of phosphoramide mustard
4. Urinary metabolites of antitumor agent cyclophosphamide
5. Clinical pharmacology of cyclophosphamide
6. Cyclosphos-phamide (NSC-26271)-related phosphoramide mustards-recent advances and historical perspective
7. Comparative effects of cyclophosphamide and phosphoramide mustard on murine hematopoietic and immunocompetent cells
8. Antineoplastic and immunosuppressive agents
9. Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolites
10. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo
11. Hanford Biology Symposium
12. 51
13. Differential aspects of cyclophosphamide on the B and T cell compartments of adult mice
14. Selective depletion of lymphoid tissue by cyclophosphamide
15. Proportional increase in the carrying lymphocytes in peripheral lymphoid tissue following treatment with cyclophosphamide
16. Effect of immunosuppressive drugs on T and B lymphocytes in guinea pigs
17. Specific acquired immune unresponsiveness to contact allergens with cyclophosphamide in the mouse
18. The effect of cytotoxic drugs on graft versus host disease in mice
19. Prolongation of homograft survival in mice with single dose of cyclophosphamide
20. On mechanism of immunological tolerance in cyclophosphamide treated mice
21. Effect of Cy on ocular immune response
22. Enhancement of DNCB contact sensitization by cyclophosphamide in guinea pigs
23. Potentiation of T cell mediated immunity by selective suppression of antibody formation with cyclophosphamide
24. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide
25. Augmentation of delayed type hypersensitivity by doses of cyclophosphamide which do not affect antibody response
26. In vitro effects of 4 hydroxyperoxycyclophosphamide on human im-munoregulatory T-subset function
27. Relative susceptibility of T-cell subsets involved in delayed type hypersensitivity to sheep RBC to the in vitro action of 4 hydroxyperoxycyclophosphamide
28. Influence of cyclophosphamide on delayed hypersensitivity and acquired cellular resistance to Listeria monocytogenes in the mouse
29. Cyclophosphamide sensitive T-lymphocytes suppress the in vivo generation of antigen specific cytotoxic T-lymphocytes
30. Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors
31. 19s and 7s antibody production in the cyclophosphamide or methotrexate treated rat
32. Further studies on B-lymphocyte suppression in delayed hypersensitivity indicating a possible mechanism for Jones-Mote hypersensitivity
33. Effect of cyclophosphamide on immunological control mechanism
34. Activation of human B-lymphocyte. XII. Differential effect of in vitro cyclophosphamide on human lymphocyte sub-population involved in B-cell activation
35. Cyclophosphamide inhibited B-cell receptor regeneration as a basis for drug induced tolerance
36. Augmentation of human immune response by cyclophosphamide
37. Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid tumor cancer patients: Correlation with rebound over short immune function recovery
38. Selective depletion of human circulating B-lymphocytes by cyclophosphamide
39. Suppression of human B-lymphocyte function by cyclophosphamide
40. Immunoregulation in autoimmunity
41. Effect of cyclophosphamide on immunological memory
42. Effect of cyclophosphamide on advanced lung cancer and hematological toxicity of large, intermittent intravenous doses
43. Intensive cyclophosphamide therapy for solid tumors
44. Effect of large intermittent intravenous doses of cyclophosphamide in lymphoma
45. Clinical evaluation of a new alkylating agent: Cytoxan (cyclophosphamide)
46. Alopecia and cytotoxic drugs
47. The course of nausea and vomiting after high dose of cyclophosphamide
48. Cyclophosphamide induced cardiomyopathy
49. Cycotoxic drug induced pulmonary disease
50. Late onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide
51. Sterility and testicular atrophy related to cyclophosphamide therapy
52. Multiple late complications of cyclophosphamide including ovarian destruction
53. Return of fertility in a patient with cyclophosphamide-induced azoospermia
54. Gonadal dysfunction in patients receiving chemotherapy for cancer
55. Genetic effects of cyclophosphamide
56. Congenital anomalies probably induced by cyclophosphamide
57. Fetal effects during cyclophosphamide and irradiation therapy
58. Normal pregnancy in multiple myeloma treated with cyclophosphamide
59. Cyclophosphamide induced chromosomal aberrations in non-tumorous patients
60. Cytostatic immunosuppressive therapy chromosomal aberrations of carcinogenic effect
61. Sister chromatid exchanges in lymphocytes from patients with malignant lymphoma
62. Sister chromatid exchange studies for monitoring DNA damage and repair capacity after cytostatic therapy
63. Sister-chromatid exchanges and chromosomal breakage in patients treated with cytostatics
64. Cytological study of the effect of cyclophosphamide on the epithelium of the urinary bladder
65. Cyclophosphamide and the urinary bladder
66. Cyclophosphamide cystitis and bladder carcinoma, a hypothesis
67. Control of ifosphamide induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung
68. International Agency for Cancer Research: Cyclophosphamide
69. Collaborative UK Australasian-study of cancer patients treated with immunosuppressive drugs
70. Cancer patients treated with immunosuppressive drugs
71. Cancer patients treated with immunosuppressive drugs
72. Intracerebral lymphoma in a patient with central nervous system lupus on cyclophosphamide
73. The incidence of bladder cancer after cyclophosphamide therapy
74. Late hemmorhagic cystitis following low-dose cyclophosphamide therapy
75. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis
76. Bladder malignancy in a patient receiving cyclophosphamide for benign diseases
77. Bladder malignancy in patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis
78. Tumors of the urinary bladder in workmen engaged in manufacture and use of certain dye stuff intermediates in the British chemical industry; role of naphthylamine and β-naphthylamine
79. Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation
80. Cyclophosphamide hepa-totoxicity in a patient with systemic lupus erythematosus
81. Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide
82. Cyclophosphamide in solid tumors
83. Possible anaphylaxis reaction to intravenous cyclophosphamide. Report of a case
84. Generalized urticaria to cyclophosphamide, type I hypersensitivity to an immunosuppressive agent
85. Oropharyngeal sensation associated with rapid intravenous administration of cyclophosphamide
86. Cyclophosphamide induced nail pigmentation
87. Immunosuppressive therapy in rheumatic diseases
88. Epipodophyl-lotoxin (VP-16-213). Mycosis fungoides: A report from the Scandinavian Mycosis Fungoides Study Group
89. Treatment of mycosis fungoides with cyclophosphamide and chlorpromazine
90. The treatment of mycosis fungoides with a new agent, cyclophosphamide (Cytoxan)
91. Treatment of mycosis fungoides with cyclophosphamide
92. A preclusive clinical trial of cyclophosphamide
93. Pharmacological treatment in organ and tissue transplantation
94. Pemphigus vulgaris successfully treated with cyclophosphamide
95. Cyclophosphamide and pemphigus vulgaris
96. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid
97. Pemphigus treated with cyclophosphamide
98. Intermittent cyclophosphamide in pemphigus vulgaris and bullous pemphigoid
99. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris
100. Immunosuppressants and prednisone in pemphigus vulgaris
101. Treatment of pemphigus with cyclophosphamide
102. Corticotropin and cortisone treatment for systemic lupus erythematosus
103. Cyclophosphamide treatment of kidney disease in (NZB and NZW) Fl mice
104. Cyclophos-phamide therapy in systemic lupus erythematosus and polymyositis
105. Cyclophosphamide in lupus nephritis. A controlled trial
106. Cyclophosphamide in the treatment of systemic lupus erythematosus, 7 yr experience
107. Cyclophosphamide in systemic lupus erythematosus
108. A sequential trial comparing cyclophosphamide and azathioprine as adjuvants in the treatment of systemic lupus erythematosus
109. Systemic lupus erythematosus. Evolving concepts
110. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
111. Cytotoxic treatment of lupus nephritis
112. Prednisolone plus azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis
113. Altemate modes of cyclophosphamide and azathioprine therapy in lupus nephritis
114. Systemic lesions of malignant rheumatoid arthritis
115. A controlled trial of cyclophosphamide in rheumatoid arthritis
116. Controlled trial of cyclophosphamide in rheumatoid arthritis
117. Cyclophosphamide therapy for rheumatoid arthritis
118. Long term cyclophosphamide therapy in rheumatoid arthritis
119. Cyclophosphamide therapy of severe systemic necrotizing vasculitis
120. Toxicity of immunosuppressive drugs in man
121. Lymphomatoid granulomatosis: Prospective clinical and therapeutic experience over 10 years
122. Wegener’s granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years
123. Cyclophosphamide induced remission in advanced polyarteritis nodosa
124. Rheumatoid vasculitis, effects of cyclophosphamide on the clinical course and levels of circulating immune complexes
125. Pyoderma gangrenosum with response to cyclophosphamide therapy
126. Pyoderma gangrenosum: Response to cyclophosphamide therapy
127. Psoriasis with arthritis; Chemotherapy with cyclophosphamide, nitrogen mustard and 6-mercaptopurine
128. Exploration of antimitotic agent in the treatment of a congenital disease, ichthyosis linearis circumflexa
129. Treatment of eczema with cyclophosphamide and azathioprine
130. Results of immunosuppressive treatment in Behçets disease: Report of 55 cases
131. Visual prognosis in Behçets disease, effects of cyclophosphamide and colchicine
132. Cyclophosphamide therapy of Behçets disease
133. Immunosuppressive therapy in polymyositis
134. Dermatomyositis: Observation on the use of immunosuppressive therapy and review of literature
135. Vasculitis with essential mixed cryoglobulinemia
136. Pattern of response to prednisone in idiopathic minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy
137. Nephrologie effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependance
138. Refractory thrombocytopenic purpura treated successfully with cyclophosphamide
139. Treatment of refractory purpura with cyclophosphamide
140. A survey of effectiveness of cyclophosphamide in patients with severe aplastic anemia
141. Treatment of active chronic hepatitis with cyclophosphamide
142. Idiopathic pulmonary hemosiderosis with manifestations of multiple connective tissue and immune disease
143. Plasma cell interstitial pneumonia and macroglobulinemia
144. Plasmaphoresis and immunosuppressive drug therapy in scleroderma
145. Cyclophosphamide for clinical renal and hepatic transplantation
146. The comparative pharmacology of cyclophosphamide and ifosfamide